Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.63 |
| ▸ | CTSK | P43235 | 9/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.60 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 5/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034396 | 1.00 | NMBR (0.63) | NMBRCTSKCAPN1CAPN2CPB1 | |
| SCHEMBL14067668 | 0.88 | CTSK (0.77) | CTSKCAPN1CAPN2CTSSCTSL | |
| SCHEMBL18758793 | 0.87 | CTSS (0.55) | CTSKCAPN1CAPN2CTSSCTSL | |
| SCHEMBL29360476 | 0.87 | NMBR (0.57) | NMBRCTSKCAPN1CAPN2CPB1 | |
| SCHEMBL6360713 | 0.87 | SMN1; SMN2 (0.56) | CTSKCAPN1CAPN2CTSSCTSL | |
| SCHEMBL9358645 | 0.86 | CTSL (0.58) | CTSKCAPN1CAPN2CTSSCTSL | |
| SCHEMBL22034521 | 0.85 | CTSS (0.58) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL22034518 | 0.85 | CTSS (0.58) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL1122463 | 0.85 | CTSS (0.58) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL14433709 | 0.85 | CTSS (0.58) | CTSKCTSSCTSLCTSBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2020118179-A1 | PEPTIDOMIMETIC INHIBITORS OF Β-CATENIN/TCF PROTEIN–PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | NMBR 3573/4885CTSK 2281/4885CAPN1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.